title: Effects of different hormone replacement regimens on postmenopausal women with abnormal lipid levels. Menopause Study Group.
abstract: OBJECTIVE
  A retrospective, subset analysis of the prospective Menopause Study Group data was performed to determine the effects of four conjugated estrogens (CE) + medroxyprogesterone acetate (MPA) regimens and one unopposed CE regimen on the lipid profiles of women with abnormal lipid levels (n = 525). Previously unpublished data on the entire study population were also reviewed to determine the effects of these hormone replacement regimens on blood pressure and weight (n = 1368, 1374, respectively).
  
  
  METHODS
  During a 1-year, prospective trial, all patients took CE. Groups A and B also took continuous MPA 2.5 and 5 mg, respectively, C and D took MPA 5 and 10 mg for the last 14 cycle days of each 28-day cycle, and E took matching placebo tablets to replace MPA.
  
  
  RESULTS
  After 1 year, all five regimens were directly associated with significant elevations in high density lipoprotein-2 (HDL2) cholesterol and significant reductions in low density lipoprotein (LDL) cholesterol (p < 0.05), although unopposed estrogen produced the greatest increase in HDL2 cholesterol. The CE + MPA regimens were also associated with significant decreases in total cholesterol. Triglyceride levels did not change significantly from baseline in any treatment group (baseline values > 1.808 mmol/l (> 160 mg/dl)), although the CE + MPA regimens were associated with a mean triglyceride decrease and CE-only women (n = 8) had a mean triglyceride increase. No regimen produced significant weight or blood pressure changes.
  
  
  CONCLUSIONS
  This analysis suggests that hormone replacement therapy (CE + MPA), used in appropriate dosages, may alter the HDL2 cholesterol and LDL cholesterol lipoproteins in postmenopausal women with borderline lipid levels (a higher-risk population) in a cardioprotective manner.
authors.affiliation: Wyeth-Ayerst Research, PO Box 8299, Philadelphia, PA 19101, USA.
authors.forename: J H
authors.initials: JH
authors.lastname: Pickar
authors.forename: R A
authors.initials: RA
authors.lastname: Wild
authors.forename: B
authors.initials: B
authors.lastname: Walsh
authors.forename: E
authors.initials: E
authors.lastname: Hirvonen
authors.forename: R A
authors.initials: RA
authors.lastname: Lobo
mesh_terms: D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004311:Double-Blind Method; D015914:Estrogen Replacement Therapy / Q000379:methods*; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D053439:Lipoproteins, HDL2; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D010919:Placebos; D017698:Postmenopause / Q000097:blood*; D011446:Prospective Studies; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004966:Estrogens, Conjugated (USP); D008055:Lipids; D008075:Lipoproteins, HDL; D053439:Lipoproteins, HDL2; D010919:Placebos; D014280:Triglycerides; D017258:Medroxyprogesterone Acetate